The essential handbook for any business developer, BI/CI operator or clinical developer

DUBLIN, June 16, 2022 /PRNewswire/ — The “CAR/TCR therapies in oncology: analytical tool” report has been added to from offer.

Research and Markets Logo

Your CAR/TCR Therapies in Oncology: Analysis Tool covers more than 173 companies and partners who are currently developing 520 CAR/TCR drugs, of which 499 are in active development in cancer on 120 different targets. All data and/or analysis in the analytics tool belongs to you and the data/graphs/tables can be easily exported to Excel/PDF and various graphical formats to be mixed with your own proprietary information.

Chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies are game changers in cancer therapies and there is a place in history and huge recognition for Novartis and Kite Pharma ( now Gilead Sciences) to be the first companies to bring these new therapies to market with Kymriah (tisagenlecleucel-t) and Yescarta (axicabtagene ciloleucel) respectively.

CAR/TCR Therapies in Oncology: Analytical Tool is the essential handbook for any commercial developer, BI/CI operator, or clinical developer who needs to master this hot and rapidly evolving field of immuno-oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your CAR/TCR drug monitoring and intelligence, enabling you to fuel your decision-making and advance your own interests.

Keep you posted”

Simply put, our mission is to fuel your immuno-oncology knowledge, make you the first to know about the very first technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape. .

Let our expertise work for you

With a simple point-and-click interface, you can navigate the current development environment, explore specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts, and more. and generate Drug Profiles, Drug Target Profiles and Company Profiles (including Business Development & Licensing Contacts). Any analysis you generate is packed with ready-to-present charts and tables for use in your reports and presentations.

Your key to accessing development at key global cancer meetings

The CAR/TCR Therapies in Oncology: Analytical Tool is continuously updated according to twelve of the world’s most influential oncology meetings (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International , Europe and Asia). If you’re unable to attend either conference in person, this analytics tool ensures you don’t miss the important take-home messages you need to know.

Run Combination Therapy Analysis Like No Other

The CAR/TCR Therapies in Oncology: Analytical Tool provides a comprehensive analysis of combination therapies, allowing you to analyze combination therapies from multiple angles; from a single drug to virtually any oncology drug sample of interest.

Unparalleled biomarker monitoring

We also provide exceptional clinical biomarker monitoring and analysis in oncology, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and use of over 1,000 biomarkers in tens of thousands of cancer clinical trials.

Support and inspiration at your fingertips

You also have access to a great selection of hands-on training videos showing best practices for things like competitive pipeline analysis to plenty of real-life case examples from other users of our analytics tools.

A tool to grow and keep you informed

Unlike a static report that only represents a particular snapshot in time, all analytics tools come with one year of online access to bi-weekly content and feature updates, pipeline alerts, and online support, etc. You can choose to renew your access. to these updates and support on an annual basis or upgrade to our industry-leading full-service platform covering all oncology drug development, 1stOncology.

CAR/TCR Therapies in Oncology: Analytical Tool achieves this by continuously analyzing the development of CAR/TCR and reporting:

  • Offers and collaborations

  • New technologies/drugs (from patents, grants, abstracts (see conference coverage), etc.)

  • Funding/Grants/IPO

  • Filings and Approvals

  • Development and results of the latest clinical trials

  • Recently launched clinical trials

  • Conference Coverage of the top 12 global oncology meetings*

  • Quarterly and annual reports

Identify, prioritize and direct the scientific assessment of opportunities and competition in oncology based on several factors such as:

  • Emerging technologies

  • Target novelty

  • Recent funding

  • Early and late stage pipeline

  • Development of companion biomarkers/diagnostics (presented below)

  • Seized offers and alliances

  • Conference monitoring of major global cancer meetings (featured below)

  • Combination therapy choices (shown below)

  • Result of clinical trials

  • Selection of indications and choice of extension

  • Drug repositioning opportunities

For more information on this report, visit

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716



Show original content: developer-301569520.html

SOURCE Research and Markets

Comments are closed.